Keisha Young-henry Pharmaceutical Import Profile — Jamaica (DGFT 2022–2026)

Name: Keisha Young-henry Pharmaceutical Import Records from India — 2 Products, $58.4K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Keisha Young-henry — Pharmaceutical Importer Profile (2026) | 2 Products, $58.4K Trade | TransData Nexus

Keisha Young-henry

Pharmaceutical Importer · Jamaica · Advanced Oncology Focus · $58.4K Total Trade · DGFT Verified

Keisha Young-henry is a pharmaceutical importer based in Jamaica with a total trade value of $58.4K across 2 products in 1 therapeutic categories. Based on 5 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Keisha Young-henry sources from 1 verified Indian supplier, with Shree Krishna Lifecare accounting for 100.0% of imports.

Keisha Young-henry — Import Portfolio & Supplier Network

Keisha Young-henry import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Keisha Young-henry?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Shree Krishna Lifecare	$139.4K	64	100.0%

Keisha Young-henry sources from 1 verified Indian supplier across 59 distinct formulations. The sourcing is highly concentrated — Shree Krishna Lifecare accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Keisha Young-henry Import?

Formulation	Value	Ships
Pembrolizumab injection 100MG/4ML (keytruda) (single vial per Box) (re-exp.of goods to third country u/s 69)	$25.7K	1
Pembrolizumab injection 100MG/4ML (keytruda) (single vial per Box) (re-export ofgoods to third country u/s 69)	$22.1K	1
Pharmaceutical product:azzated 100 (azacitidine for injection 100MG)	$7.0K	1
Pharmaceutical product : herduo (lapatinib tablets i.p 250MG)	$5.0K	1
Ujvira 100MG (trastuzumab emtansine 100MG injection)	$4.9K	1
Pharmaceutical-herduo (lapatinib tablets i.p 250MG)	$4.7K	1
Pharmaceutical product: krabeva (bevacizumab 400MG/16ML injection) (4 vials)	$4.4K	1
Pharmaceutical product : everbliss 10mgtab ( everolimus tablets 10m) ( Pack = nos)	$3.2K	2
Pharmaceutical product :- ibrunat 140 (ibrutinib 140 MG capsules)	$3.2K	1
Surgical product : acabrunat-acalabrutinib 100MG capsules Pack type-	$3.0K	1
Pharmaceutical product :- taxonab 100MG(paclitaxel-protein bound particles forinjectable suspension 100MG)	$2.8K	1
Krabeva (bevacizumab 400MG/16ML injection (4 vials)	$2.4K	1
Pharmaceutical product : acabrunat - acalabrutinib capsules 100MG Pack type 30s	$2.4K	1
Anagrelide cap 0.5MG (100)-viatris (Pack:100'sx6) (re-export of goods to third country u/s 69)	$2.4K	1
Pharmaceutical product : "hertupal 125 (palbociclib 125MG capsules)	$2.1K	1

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Pembrolizumab	Advanced Oncology	$47.8K	2	2.5%	6
2	Lapatinib	Advanced Oncology	$10.6K	3	0.2%	7

Keisha Young-henry imports 2 pharmaceutical products across 1 categories into Jamaica totaling $58.4K.

Keisha Young-henry — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Keisha Young-Henry is a pharmaceutical importer and buyer based in Kingston, Jamaica. Operating as an independent entity, she specializes in sourcing and importing finished pharmaceutical formulations from India to meet the healthcare needs of the Jamaican market. Her role is pivotal in ensuring the availability of essential medications, particularly in the oncology therapeutic category, thereby contributing significantly to the country's healthcare infrastructure.

2Distribution Network

While specific details about Keisha Young-Henry's warehouse locations and logistics capabilities are not publicly disclosed, her operations are centered in Kingston, the capital city of Jamaica. This strategic location facilitates efficient distribution across the island, ensuring timely delivery of imported pharmaceutical products to various healthcare facilities and pharmacies. The choice of Kingston as a hub underscores the importance of accessibility and connectivity in her distribution strategy.

3Industry Role

In Jamaica's pharmaceutical supply chain, Keisha Young-Henry functions primarily as a pharmaceutical importer and buyer. She is responsible for sourcing finished pharmaceutical formulations from international suppliers, particularly from India, and ensuring their availability in the Jamaican market. By focusing on the importation of oncology medications, she plays a crucial role in addressing the therapeutic needs of patients requiring specialized cancer treatments.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Keisha Young-henry

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Keisha Young-Henry's sourcing strategy exhibits a high degree of concentration, with a total import value of $58,000 USD from India across five shipments. The portfolio is entirely focused on two products: Pembrolizumab ($48,000 USD) and Lapatinib ($11,000 USD), both within the advanced oncology therapeutic category. This concentrated approach suggests a strategic decision to specialize in specific high-demand oncology medications, potentially enhancing her expertise and negotiating power with suppliers. However, the reliance on a single supplier, SHREE KRISHNA LIFECARE, for all imports introduces a risk of supply chain disruption. Diversifying the supplier base could mitigate this risk and ensure a more resilient supply chain.

2Supply Chain Resilience

The resilience of Keisha Young-Henry's supply chain is currently limited due to the exclusive reliance on SHREE KRISHNA LIFECARE for all imported products. This single-source dependency heightens the vulnerability to potential disruptions, such as production delays or logistical challenges. To enhance supply chain resilience, it would be prudent to establish relationships with additional suppliers, thereby diversifying the sourcing strategy. Additionally, ensuring that all suppliers comply with international Good Manufacturing Practices (GMP) standards is essential to maintain product quality and regulatory compliance.

Importing Pharmaceuticals into Jamaica — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Jamaica

1Regulatory Authority & Framework

In Jamaica, the Ministry of Health & Wellness is the primary regulatory authority overseeing the importation and distribution of pharmaceutical products. The Standards and Regulation Division within the Ministry is responsible for product registration, import permit processing, and the monitoring of healthcare facilities. According to the Food and Drugs Act, 1964, all pharmaceutical products, including prescription and over-the-counter drugs, herbal preparations, and natural health products, must be registered with the Ministry before importation and sale. This regulatory framework ensures that imported pharmaceuticals meet the required safety, efficacy, and quality standards. (moh.gov.jm)

2Import Licensing & GMP

Import licensing is mandatory for pharmaceutical products entering Jamaica. Importers must obtain an import permit from the Ministry of Health & Wellness, which involves submitting an application along with the necessary documentation, such as a supplier invoice, certificate of origin, and bill of lading. Additionally, the imported products must comply with international Good Manufacturing Practices (GMP) standards, such as those recognized by the World Health Organization (WHO) or the Pharmaceutical Inspection Co-operation Scheme (PIC/S). This ensures that the products are manufactured to the highest quality standards, safeguarding public health. (moh.gov.jm)

Keisha Young-henry — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Keisha Young-Henry's focus on importing advanced oncology medications, specifically Pembrolizumab and Lapatinib, aligns with the growing demand for cancer treatments in Jamaica. The selection of these products indicates a strategic decision to address critical therapeutic needs in the oncology sector. Market demand for such specialized treatments is driven by increasing cancer incidence rates and the need for effective therapies. By concentrating on this niche, Keisha Young-Henry can establish a strong market presence and cater to a specific patient population requiring advanced oncology care.

2Sourcing Profile

Keisha Young-Henry's sourcing strategy is centered on importing generic drugs from India, focusing on specific formulations within the oncology therapeutic category. This approach allows for cost-effective procurement while ensuring access to essential medications. India's well-established pharmaceutical industry, known for its adherence to international GMP standards, makes it a reliable source for high-quality generic drugs. By leveraging this sourcing profile, Keisha Young-Henry can maintain a competitive edge in the Jamaican market.

3Market Positioning

Seller's Guide — How to Become a Supplier to Keisha Young-henry

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the Jamaican market by meeting the specific quality and regulatory standards required by the Ministry of Health & Wellness. Diversifying the supplier base can enhance supply chain resilience and mitigate risks associated with single-source dependency. Identifying gaps in Keisha Young-Henry's current sourcing, such as the inclusion of additional oncology medications or other therapeutic areas, can provide avenues for new suppliers to establish partnerships and expand their market presence in Jamaica.

2Requirements & Qualifications

Indian exporters seeking to supply pharmaceutical products to Keisha Young-Henry and the Jamaican market must ensure that their products are registered with the Ministry of Health & Wellness in Jamaica. This involves submitting the necessary documentation, including a supplier invoice, certificate of origin, and bill of lading. Additionally, products must comply with international GMP standards recognized by authorities such as the WHO or PIC/S. Adhering to these requirements is essential for gaining approval and maintaining a successful business relationship in the Jamaican market.

How to Approach

Frequently Asked Questions — Keisha Young-henry

What products does Keisha Young-henry import from India?

Keisha Young-henry imports 2 pharmaceutical products across 1 categories. Top imports: Pembrolizumab ($47.8K), Lapatinib ($10.6K).

Who supplies pharmaceuticals to Keisha Young-henry from India?

Keisha Young-henry sources from 1 verified Indian suppliers. The primary supplier is Shree Krishna Lifecare (100.0% of imports, $139.4K).

What is Keisha Young-henry's total pharmaceutical import value?

Keisha Young-henry's total pharmaceutical import value from India is $58.4K, based on 5 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Keisha Young-henry focus on?

Keisha Young-henry imports across 1 categories. The largest: Advanced Oncology (100.0%).

Get Full Keisha Young-henry Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.